


PHARMACEUTICAL 2022

AILERON THERAPEUTICS INC Rank 161 of 466







PHARMACEUTICAL 2022

AILERON THERAPEUTICS INC Rank 161 of 466

The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 108% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	48,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,508
Liabilities, Non-Current	69
Other Assets	176
Other Compr. Net Income	-11
Other Expenses	0
Other Liabilities	0
Other Net Income	441
Other Revenues	0
Property and Equipment	128
Research and Development	17,008
Selling, General and Administrative Expense	9,597

Output Variable	Value in 1000 USD
Assets	48,481
Liabilities	4,577
Expenses	26,605
Revenues	0
Stockholders Equity	43,904
Net Income	-26,164
Comprehensive Net Income	-26,170
Economic Capital Ratio	186%

